Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Simcere-Sanbexin

More Like This

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

PR Newswire associated0

Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

PR Newswire associated0

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

New Study Demonstrates that SL-NAD+ delivers NAD+ into Cells

PR Newswire associated0

VST BIO Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Monoclonal Antibody to Treat Ischemic Stroke at AHA International Stroke Conference

PR Newswire associated0

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

PR Newswire associated0

Servier's Vorasidenib Receives Approval as Clinical Urgently Needed Drug to be Used in Boao Lecheng Pilot Zone

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA